Q-omics provides the consensus-scored GRAP profile across patient tissues and cancer cell-line models. GRAP expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GRAP is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GRAP protein abundance shows 23,805 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where GRAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAP survival associations across molecular data types. GRAP RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAP RNA expression–survival associations across cancer types. High GRAP expression shows unfavorable associations in KIRP, MESO and LGG, but favorable associations in HNSC, KIRC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GRAP RNA expression.
This table summarizes GRAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GRAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAP shows lower tumor expression in LUSC, KICH, KIRP and LUAD and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher GRAP RNA expression in tumor versus normal tissue (log2 FC = +0.870, t-test p < 0.001).
This table shows molecular features associated with GRAP in patient tissues and cancer cell lines. In patient samples, GRAP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GRAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER.
